Sidley represented Yuhan Corporation in its licensing agreement with Janssen, a division of Johnson & Johnson, for the development, manufacturing and commercialization of lazertinib, a non-small cell lung cancer drug candidate. Janssen agreed to pay Yuhan $50 million in upfront money with the potential for significant milestone and royalty payments that could amount to the total of $1.25 billion if the drug earns regulatory approval. The deal was led by partner Josh Hofheimer (Los Angeles) with counsel Lauren Grau (Dallas).
Sidley Represents Yuhan Corporation in Licensing Agreement with Janssen
January 17, 2019